PD-L1
2 drugsProgrammed Death-Ligand 1
Predictive biomarker for patient selection in 6 indications
Understanding PD-L1
What it means: PD-L1 is a protein expressed by cancer cells that binds to PD-1 on T cells, suppressing immune response.
Why it matters: High PD-L1 expression often predicts better response to checkpoint inhibitors like pembrolizumab and nivolumab.
Testing: Tested via immunohistochemistry (IHC) with various scoring methods: TPS (Tumor Proportion Score) and CPS (Combined Positive Score).
2
Approved Drugs
6
Indications
2
Companies
PD-L1 is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 6 indications including Metastatic Merkel cell carcinoma in adults and pediatric patients 12 years and older, Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, Locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 drugs below.
Search PD-L1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1
PD-L1 Indications
Metastatic Merkel cell carcinoma in adults and pediatric patients 12 years and older Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy Locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy Locally advanced or metastatic urothelial carcinoma with disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy First-line treatment of advanced renal cell carcinoma in combination with axitinib Cutaneous Squamous Cell Carcinoma